Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)

Stocks tumbled on Friday to close out a brutal week for financial markets as surging interest rates and foreign currency turmoil heightened fears of a global recession. Dow drops nearly 600 points into the bear market territory, sets a new low for the year. With central banks rapidly raising rates to control inflation, fears of a recession are rising and making all assets toxic for investors these days. Treasury yields in the U.S. surged again Friday, with the 2-year note most sensitive to Federal Reserve rate hikes, jumping 7.4 basis points to 4.2% around noon ET.

Does this drop provide an opportunity to buy the dip in companies with excellent fundamentals, such as biotech stocks?

President Joe Biden is launching a new initiative to encourage biotech production and research in the U.S. Earlier this month, he signed an executive order implementing the initiative and later will address how biotech can help fight cancer, though the amount of funding the White House is setting aside for it is unclear. Let’s look at some of the biotech stocks out there currently trading at discount prices in our opinion.

Mainz Biomed N.V. (NASDAQ:MYNZ) is a molecular genetics diagnostic company specializing in the early detection of cancer. The Company recently announced the appointment of Dr. Douglas K. Rex to its Medical Advisory Board (MAB). Dr. Rex is the latest industry expert to join the MAB which was established to support Mainz’s forthcoming U.S. pivotal trial for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). Mainz Biomed B.V. (MYNZ) is currently trading closer to the 7$ mark compared it its 52-week low of $6.07. MYNZ has a 52-week high of $30.00, suggesting there exists a lot of room for the upside. It would be interesting to see if the ColoAlert picks up pace in the medical community and boost revenues for Mainz Biomed N.V. (NASDAQ:MYNZ).

ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVDR marked (complying with EU safety, health, and environmental requirements). The product is commercially available in a selection of countries in the European Union and in the United Arab Emirates. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

Mainz is currently marketing ColoAlert through its unique business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. 

Some of the other notable biotech stocks to watch out for include Revance Therapeutics Inc (NASDAQ:RVNC), CinCor Pharma (NASDAQ:CINC), Reata Pharmaceuticals (NASDAQ:RETA), Supernus Pharmaceuticals (NASDAQ:SUPN), Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ), Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).


Disclaimer: InvestorBrandMedia is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available in this article is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall Investor Brand Media be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by Investor Brand Media ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Investor Brand Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. Investor Brand Media has been compensated four thousand two hundred and fifty dollars by a 3rd party Bullyzeye Media LLC for content, research, dissemination, and syndication, web push advertisement services pertaining to MYNZ from 09/25/2022 to 09/29/2022. We own zero shares of MYNZ. 

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: Send Email
Country: United States